The FDA approved label expansions for bempedoic acid (Nexletol) and bempedoic acid/ezetimibe (Nexlizet) so they can be used more broadly as cardiovascular prevention drugs, Esperion announced Friday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback